ConjuLean 1000™

Patented Conjugated Linoleic Acid in a Pure 78% Form (780 mg)



Available in 120 softgels

Clinical Applications

- » Maintains Healthy Body Composition*
- » Lessens Catabolic Effect of Training on Muscle Protein*
- » Supports Anti-Inflammatory Pathways*

ConjuLean 1000™ is a patented formula offering a beneficial dose of pure Conjugated Linoleic Acid (CLA) in just four softgels. Each softgel contains an average of 78% (780 mgs) pure CLA consisting of the highest concentration of those isomers most commonly associated with health benefits. ConjuLean 1000™ is manufactured in a facility dedicated solely to CLA to ensure consistency of quality.*

Discussion

The body cannot manufacture CLA, a naturally-occurring mixture of linoleic acid isomers with conjugated double bonds. The average daily consumption is 15-174 mg, mostly from meat and dairy. Conjugated linoleic acid isomers have been shown to possibly reduce body fat mass, enhance immune response and modulate inflammation via inhibition of Cox-2 and prostaglandin synthesis. [1,2] In the rodent model CLA also stimulated PPAR synthesis, decreased macrophage accumulation and induced apoptosis in an atherosclerotic lesion.*[3]

Although anticarcinogenic, antiatherogenic, antidiabetic, and antiobesity properties of CLA have been well-documented in rodents, these properties are still under investigation in humans. Results of human CLA studies may vary due to the isomers studied, selection of the subjects, diet and lifestyle guidelines, method of body composition assessment and/or study length. [4] Outcomes appear to be best in women and in those with the highest BMI.*[5]

In a randomized double-blind, placebo-controlled, three-month study with 60 overweight or obese volunteers, receiving either 1.7, 3.4, 5.1 or 6.8 grams CLA daily, a significantly higher reduction in body fat mass (BFM)(P=0.03) was seen in all CLA groups compared to placebo; however, no further reduction in BFM occurred with doses >3.4 grams.*

In 2004, the first double-blind, placebo-controlled study was performed in healthy overweight subjects without specific diet/lifestyle restrictions to document the long-term (1 year) safety and efficacy of CLA supplementation. Employing DXA technology, the mean (\pm SD) BFM in the CLA groups was 8.7 \pm 9.1% and 6.9 \pm 9.1%, respectively, lower than that in the placebo group (P < 0.001). LBM in volunteers receiving CLA was 1.8 \pm 4.3% greater than the placebo group (P = 0.002). Following volunteers on CLA for 24 months, an open study (n =134) reconfirmed CLA supplementation in healthy, overweight adults is well tolerated, decreases BFM in overweight humans and may help maintain initial reductions in BFM and weight in the long term. $^{*[7]}$

Other studies have shown that CLA may have a defensive role in breast cancer and colon cancer.^[8,9] CLA also appears to lessen the catabolic effect of resistant training upon muscle protein.^[10] A recent study in 44 healthy young women concluded supplementing CLA alone or with exercise seems effective on serum glucose and insulin concentrations.*^[11]

ConjuLean 1000™ Supplement Facts

Serving Size: 1 Softgel

	Amount Per Serving	%Daily Value
Providing:	1000 mg	**
Conjugated Linoleic Acid (CLA)		
Pure Conjugated Linoleic Acid [typical]	780 mg	**
** Daily Value not established.		

Other Ingredients: Gelatin, glycerin, and purified water.

DIRECTIONS: Take one to two softgels twice daily with food or as directed by your healthcare practitioner.

DOES NOT CONTAIN: Wheat, gluten, corn protein, yeast, soy protein, dairy products, artificial colors, sweeteners or preservatives.

CAUTION: Keep out of reach of children.

STORAGE: Keep tightly closed in a cool, dry place.

References

- Li G,et al. 10t,12c-conjugated linoleic acid inhibits lipopolysaccharideinduced cyclooxygenase expression in vitro and in vivo. J Lipid Res. 2005 0ct;46(10):2134-42. Epub 2005 Aug 1 [PMID: 16061956]
- Zhang JS, et al. [Role of cyclooxygenase-2 in inhibition of human gastric adenocarcinoma cell line SGC-7901 by c9, t11-conjugated linoleic acid] Wei Sheng Yan Jiu. 2005 May;34(3):333-5 [PMID: 16111045]
- Toomey S, et al. Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis. 2006 Jul;187(1):40-9. Epub 2005 Sep 22 [PMID: 16182300]
- Navarro V, The body fat-lowering effect of conjugated linoleic acid: a comparison between animal and human studies. J Physiol Biochem. 2006 Jun;62(2):137-47. [PMID: 17217167]
- Blankson H, et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr 2000;130:2943–8
- Gaullier JM, et.al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr. 2004 Jun;79(6):1118-25 [PMID: 15159244]
- Gaullier JM, et al. Supplementation with Conjugated Linoleic Acid for 24 Months Is Well Tolerated by and Reduces Body Fat Mass in Healthy, Overweight Humans The American Society for Nutritional Sciences. J Nutr. April 2005;135:778-784
- O'Shea M, Stanton C, Devery R. Antioxidant enzyme defense responses of human MCF-7 and SW480 cancer cells to conjugated linoleic acid. Anticancer Res 1999;19:1953-60
- Sebedio JL, Gnaedig S, Chardigny JM. Recent advances in conjugated linoleic acid research. Curr Opin Clin Nutr Metab Care 1999;2:499-506
- Pinkoski C, The effects of conjugated linoleic acid supplementation during resistance training. Med Sci Sports Exerc. 2006 Feb;38(2):339-48 [PMID: 16531905]
- Colakoglu S.Cumulative effects of conjugated linoleic acid and exercise on endurance development, body composition, serum leptin and insulin levels. J Sports Med Phys Fitness. 2006 Dec;46(4):570-7 [PMID: 17119522]
- 12. Conjugated Linoleic Acid. www.naturaldatabase.com {accessed 3.5.07}